- Conditions
- Chronic Kidney Diseases
- Interventions
- Empagliflozin 10 MG, Placebo
- Drug
- Lead sponsor
- Washington D.C. Veterans Affairs Medical Center
- Federal
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypertension, Cardiovascular Diseases
- Interventions
- empagliflozin, Placebo tablet
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- empagliflozin, metformin, sulfonylurea
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ridgefield, Connecticut
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773, Glimepiride, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- semaglutide, empagliflozin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Tuscumbia, Alabama • Encino, California • La Mesa, California + 39 more
- Conditions
- Type2Diabetes, ASCVD
- Interventions
- SGLT2 inhibitor, GLP-1 receptor agonist
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
- Conditions
- Diabetes
- Interventions
- Empagliflozin, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 103,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Kidney Transplant, Chronic Kidney Disease
- Interventions
- Empagliflozin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 19 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
- Conditions
- Liver Diseases, Hypertension, Portal
- Interventions
- Avenciguat, Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo to Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Orange, California • Torrance, California + 25 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 34
- States / cities
- Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more
- Conditions
- Alzheimer Disease
- Interventions
- Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,988 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 135
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
- Conditions
- Type2diabetes, Heart Failure With Reduced Ejection Fraction
- Interventions
- Empagliflozin 25 MG Oral Tablet, Placebo, Acipimox 250 Mg Oral Capsule
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2, Hypertension
- Interventions
- Placebo, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Fresno, California
- Conditions
- Cirrhosis, Liver Failure
- Interventions
- Empagliflozin 10 MG, Matching Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- SGLT2i, No SGLT2i
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
- Interventions
- Empagliflozin, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23,955 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Epilepsy
- Interventions
- Empagliflozin 25 mg, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 2 Diabetes
- Interventions
- Empagliflozin 25 MG, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas